title: Buspirone and imipramine for the treatment of major depression in the elderly.
abstract: BACKGROUND
  The current study was designed to assess the safety and efficacy of imipramine and buspirone in the treatment of major depression in elderly depressed attendees of primary care practices.
  
  
  METHODS
  177 patients aged 65 and over (mean age = 72 years; range, 65-89) who met DSM-III-R criteria of unipolar major depression with a minimum Hamilton Rating Scale for Depression score of 18 were randomly assigned to 8 weeks of double-blind, placebo-controlled treatment with flexible doses of either imipramine or buspirone.
  
  
  RESULTS
  Moderate to marked global improvement after 8 weeks of treatment (LOCF analysis) occurred in 70% of patients treated with imipramine, 61% of patients treated with buspirone, and 42% of patients treated with placebo (chi2 = 9.1, df = 2, p < .02). Drug treatment was well tolerated, with 77% of imipramine- and 61% of buspirone-treated patients completing 8 weeks of therapy. Imipramine/placebo differences were present from week 2 on, but buspirone/placebo differences occurred only at week 8. The presence of comorbid medical illness or concomitant use of nonpsychiatric prescription medications was not associated with poorer antidepressant response, increased adverse effects, or study attrition.
  
  
  CONCLUSIONS
  Imipramine and to a lesser extent buspirone were found to be effective and well tolerated in the treatment of elderly depressed outpatients.
authors.affiliation: Department of Psychiatry, University of Pennsylvania, Philadelphia, USA.
authors.forename: E
authors.initials: E
authors.lastname: Schweizer
authors.forename: K
authors.initials: K
authors.lastname: Rickels
authors.forename: H
authors.initials: H
authors.lastname: Hassman
authors.forename: F
authors.initials: F
authors.lastname: Garcia-España
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002065:Buspirone / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D011320:Primary Health Care; D011569:Psychiatric Status Rating Scales; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000929:Antidepressive Agents, Tricyclic; D010919:Placebos; D017366:Serotonin Receptor Agonists; D007099:Imipramine; D002065:Buspirone